Related Experiment Video

Updated: Jul 9, 2026

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

C-type natriuretic peptide and its relation to non-invasive indices of left ventricular function in patients with

S Del Ry1, M Maltinti, M Cabiati

  • 1CNR Institute of Clinical Physiology, Laboratory of Cardiovascular Biochemistry, Via Giuseppe Moruzzi 1, 56124 Pisa, Italy. delry@ifc.cnr.it <delry@ifc.cnr.it>

Peptides
|December 8, 2007
PubMed

Insights

C-type natriuretic peptide (CNP) levels are elevated in chronic heart failure (CHF) patients. Higher CNP concentrations correlate with impaired left ventricular (LV) function, particularly with dP/dt, suggesting a role in cardiac contractility.

Area of Science:

  • Cardiology
  • Biochemistry
  • Physiology

Background:

  • C-type natriuretic peptide (CNP) levels are elevated in chronic heart failure (CHF) patients, correlating with disease severity.
  • Understanding the relationship between CNP and cardiac function is crucial for managing CHF.

Purpose of the Study:

  • To investigate the correlation between circulating CNP concentrations and left ventricular (LV) function indices in CHF patients.
  • To assess the relationship between CNP levels and load-independent parameters like dP/dt.

Main Methods:

  • Evaluated LV ejection fraction (EF), LV end-diastolic dimension (LVEDD), and LV dP/dt in 38 CHF patients and 63 controls.
  • Measured plasma CNP levels in all participants.

Main Results:

  • CNP levels were significantly higher in CHF patients (7.19 pg/ml) compared to controls (2.52 pg/ml).
  • A significant negative correlation was found between dP/dt and CNP levels (r=-0.61, p<0.0001).
  • Correlations were also observed with EF (r=-0.55, p<0.001) and LVEDD (r=0.316, p<0.05).

Conclusions:

  • This study demonstrates a significant correlation between CNP and dP/dt in CHF patients.
  • Findings suggest a potential role for CNP in modulating cardiac contractility in chronic heart failure.

More Related Videos

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment08:49

Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment

Published on: August 2, 2024

Isolation of Atrial Myocytes from Adult Mice08:34

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...